AstraZeneca Signs US$1.2 B RNA Modification Partnership with Accent Therapeutics

By Michelle Liu

Pharma Deals Review: Vol 2020 Issue 6 (Table of Contents)

Published: 11 Jun-2020

DOI: 10.3833/pdr.v2020.i6.2543     ISSN: 1756-7874

Section: Research & Development



Building on its oncology presence, AstraZeneca has partnered with Accent Therapeutics on targeting RNA-modifying proteins (RMPs) for the treatment of cancer in a deal worth up to US$1...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details